TRDA (STOCKS)
Entrada Therapeutics, Inc. Common Stock
$6.575000
+0.115000 (+1.78%)
Prev close: $6.460000
Company Information
- Exchange
- XNAS
- Sector
- Health Technology
- Industry
- Biotechnology
- CEO
- Dipal Doshi
- Asset Type
- stocks
- Website
- Visit
Fundamentals
- Market Cap
- $255.44M
- Employees
- 183
- P/E (TTM)
- -1.64
- P/B (TTM)
- 0.93
- Dividend Yield
- —
Technical Indicators
- SMA 10
- —
- SMA 20
- —
- SMA 50
- —
- EMA 9
- —
- EMA 21
- —
- RSI
- —
- MACD State
- —
Recent News
No recent news found for this ticker.
Financial Statements
| Revenues | $5.74M |
| Benefits Costs and Expenses | $0.00 |
| Costs And Expenses | $184.15M |
| Operating Expenses | $184.15M |
| Research and Development | $143.25M |
| Other Operating Expenses | $40.90M |
| Operating Income/Loss | -$178.41M |
| Income/Loss From Continuing Operations After Tax | -$166.12M |
| Income/Loss From Continuing Operations Before Tax | -$39.32M |
| Income Tax Expense/Benefit | $962.00K |
| Net Income/Loss | -$166.12M |
| Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Net Income/Loss Attributable To Parent | -$166.12M |
| Net Income/Loss Available To Common Stockholders, Basic | -$166.12M |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
| Preferred Stock Dividends And Other Adjustments | $0.00 |
| Basic Earnings Per Share | -$3.99 |
| Diluted Earnings Per Share | -$3.99 |
| Basic Average Shares | 124,715,972 |
| Diluted Average Shares | 124,715,972 |
| Assets | $335.52M |
| Current Assets | $266.87M |
| Cash | $254.90M |
| Other Current Assets | $11.97M |
| Noncurrent Assets | $68.65M |
| Fixed Assets | $6.51M |
| Other Non-current Assets | $62.14M |
| Liabilities | $64.66M |
| Current Liabilities | $19.20M |
| Accounts Payable | $2.93M |
| Wages | $3.51M |
| Other Current Liabilities | $12.75M |
| Noncurrent Liabilities | $45.47M |
| Equity | $270.85M |
| Equity Attributable To Noncontrolling Interest | $0.00 |
| Equity Attributable To Parent | $270.85M |
| Liabilities And Equity | $335.52M |
| Net Cash Flow From Operating Activities | -$131.70M |
| Net Cash Flow From Operating Activities, Continuing | -$131.70M |
| Net Cash Flow From Investing Activities | $139.01M |
| Net Cash Flow From Investing Activities, Continuing | $139.01M |
| Net Cash Flow From Financing Activities | $637.00K |
| Net Cash Flow From Financing Activities, Continuing | $637.00K |
| Net Cash Flow | $7.95M |
| Net Cash Flow, Continuing | $7.95M |
| Comprehensive Income/Loss | -$166.27M |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0.00 |
| Comprehensive Income/Loss Attributable To Parent | -$166.31M |
| Other Comprehensive Income/Loss | -$44.29M |
| Other Comprehensive Income/Loss Attributable To Parent | -$191.00K |